51
|
Duong LT, Pickarski M, Cusick T, Chen CM, Zhuo Y, Scott K, Samadfam R, Smith SY, Pennypacker BL. Effects of long term treatment with high doses of odanacatib on bone mass, bone strength, and remodeling/modeling in newly ovariectomized monkeys. Bone 2016; 88:113-124. [PMID: 27126999 DOI: 10.1016/j.bone.2016.04.024] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/05/2016] [Revised: 03/22/2016] [Accepted: 04/24/2016] [Indexed: 12/30/2022]
Abstract
The objectives here were to evaluate the effects of odanacatib (ODN) at doses exceeding the clinical exposure on biomechanical properties of lumbar vertebrae (LV), hip and central femur (CF), and compare ODN to alendronate (ALN) on bone remodeling/modeling in ovariectomized (OVX) monkeys. Ten days post-surgery, animals were treated with vehicle (VEH), ODN-L (2mg/kg/day, p.o.), ODN-H (8/4mg/kg/day), or ALN (30μg/kg/week, s.c.) for 20months. An intact group was also included. ODN-L provided systemic exposures of 1.8-fold of clinical exposure. ODN-H started at 20-fold for 5.5months, and then reduced to 7.8-fold of clinical exposure, compared to ALN at approximated clinical exposure. From cross sectional analyses, LV density and peak load in ODN at both doses or ALN were not different from VEH or Intact. However, cortical thickness of femoral neck (FN) and CF in ODN were higher (21-34%, p<0.05) than VEH, due to smaller endocortical (Ec) perimeter of FN (10-11%; p<0.05) and CF (9-12%; ODN-L, p<0.05), and larger CF periosteal (Ps) perimeter (2-12%; ODN-H, p<0.001) versus VEH. ODN groups also showed slightly higher cortical porosity and Ps non-lamellar bone in CF. ODN-H treatment resulted in higher CF peak load (p<0.05) versus VEH. For all bone sites analyzed, a positive, linear relationship (r(2)=0.46-0.69, p<0.0001) of peak load to density or structural parameters was demonstrated. No treatment-related differences in the derived intrinsic strength properties were evidenced as compared between groups. ALN reduced all remodeling surfaces without affecting Ps modeling. Trabecular and intracortical remodeling were reduced in ODN groups, similar to ALN. Ec mineralizing surface in ODN-H trended to be lower than VEH by month 20, but Ec bone formation indices in ODN groups generally were not different from VEH. Ps modeling in ODN groups was significantly higher than other treatment groups. This study overall demonstrated the bone safety profile of ODN and its unique mechanism on cortical bone supporting the clinical application for osteoporosis treatment.
Collapse
Affiliation(s)
- L T Duong
- Bone Biology Group, Merck Research Laboratories, West Point, PA, USA.
| | - M Pickarski
- Bone Biology Group, Merck Research Laboratories, West Point, PA, USA
| | - T Cusick
- Bone Biology Group, Merck Research Laboratories, West Point, PA, USA
| | - C M Chen
- Bone Biology Group, Merck Research Laboratories, West Point, PA, USA
| | - Y Zhuo
- Bone Biology Group, Merck Research Laboratories, West Point, PA, USA
| | - K Scott
- Bone Biology Group, Merck Research Laboratories, West Point, PA, USA
| | - R Samadfam
- Charles River Laboratories, Preclinical Services Montreal, Quebec, Canada
| | - S Y Smith
- Charles River Laboratories, Preclinical Services Montreal, Quebec, Canada
| | - B L Pennypacker
- Bone Biology Group, Merck Research Laboratories, West Point, PA, USA
| |
Collapse
|
52
|
Flanagan-Steet H, Aarnio M, Kwan B, Guihard P, Petrey A, Haskins M, Blanchard F, Steet R. Cathepsin-Mediated Alterations in TGFß-Related Signaling Underlie Disrupted Cartilage and Bone Maturation Associated With Impaired Lysosomal Targeting. J Bone Miner Res 2016; 31:535-48. [PMID: 26404503 PMCID: PMC4808492 DOI: 10.1002/jbmr.2722] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/03/2015] [Revised: 09/21/2015] [Accepted: 09/23/2015] [Indexed: 11/11/2022]
Abstract
Hypersecretion of acid hydrolases is a hallmark feature of mucolipidosis II (MLII), a lysosomal storage disease caused by loss of carbohydrate-dependent lysosomal targeting. Inappropriate extracellular action of these hydrolases is proposed to contribute to skeletal pathogenesis, but the mechanisms that connect hydrolase activity to the onset of disease phenotypes remain poorly understood. Here we link extracellular cathepsin K activity to abnormal bone and cartilage development in MLII animals by demonstrating that it disrupts the balance of TGFß-related signaling during chondrogenesis. TGFß-like Smad2,3 signals are elevated and BMP-like Smad1,5,8 signals reduced in both feline and zebrafish MLII chondrocytes and osteoblasts, maintaining these cells in an immature state. Reducing either cathepsin K activity or expression of the transcriptional regulator Sox9a in MLII zebrafish significantly improved phenotypes. We further identify components of the large latent TGFß complex as novel targets of cathepsin K at neutral pH, providing a possible mechanism for enhanced Smad2,3 activation in vivo. These findings highlight the complexity of the skeletal disease associated with MLII and bring new insight to the role of secreted cathepsin proteases in cartilage development and growth factor regulation.
Collapse
Affiliation(s)
| | - Megan Aarnio
- Complex Carbohydrate Research Center, University of Georgia, Athens, GA, USA
| | - Brian Kwan
- Complex Carbohydrate Research Center, University of Georgia, Athens, GA, USA
| | | | - Aaron Petrey
- Complex Carbohydrate Research Center, University of Georgia, Athens, GA, USA
| | - Mark Haskins
- Departments of Pathology and Clinical Studies, University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, USA
| | | | - Richard Steet
- Complex Carbohydrate Research Center, University of Georgia, Athens, GA, USA
| |
Collapse
|
53
|
Andrade SS, Gouvea IE, Silva MCC, Castro ED, de Paula CAA, Okamoto D, Oliveira L, Peres GB, Ottaiano T, Facina G, Nazário ACP, Campos AHJFM, Paredes-Gamero EJ, Juliano M, da Silva IDCG, Oliva MLV, Girão MJBC. Cathepsin K induces platelet dysfunction and affects cell signaling in breast cancer - molecularly distinct behavior of cathepsin K in breast cancer. BMC Cancer 2016; 16:173. [PMID: 26931461 PMCID: PMC4774035 DOI: 10.1186/s12885-016-2203-7] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2015] [Accepted: 02/17/2016] [Indexed: 11/12/2022] Open
Abstract
Background Breast cancer comprises clinically and molecularly distinct tumor subgroups that differ in cell histology and biology and show divergent clinical phenotypes that impede phase III trials, such as those utilizing cathepsin K inhibitors. Here we correlate the epithelial-mesenchymal-like transition breast cancer cells and cathepsin K secretion with activation and aggregation of platelets. Cathepsin K is up-regulated in cancer cells that proteolyze extracellular matrix and contributes to invasiveness. Although proteolytically activated receptors (PARs) are activated by proteases, the direct interaction of cysteine cathepsins with PARs is poorly understood. In human platelets, PAR-1 and −4 are highly expressed, but PAR-3 shows low expression and unclear functions. Methods Platelet aggregation was monitored by measuring changes in turbidity. Platelets were immunoblotted with anti-phospho and total p38, Src-Tyr-416, FAK-Tyr-397, and TGFβ monoclonal antibody. Activation was measured in a flow cytometer and calcium mobilization in a confocal microscope. Mammary epithelial cells were prepared from the primary breast cancer samples of 15 women with Luminal-B subtype to produce primary cells. Results We demonstrate that platelets are aggregated by cathepsin K in a dose-dependent manner, but not by other cysteine cathepsins. PARs-3 and −4 were confirmed as the cathepsin K target by immunodetection and specific antagonists using a fibroblast cell line derived from PARs deficient mice. Moreover, through co-culture experiments, we show that platelets activated by cathepsin K mediated the up-regulation of SHH, PTHrP, OPN, and TGFβ in epithelial-mesenchymal-like cells from patients with Luminal B breast cancer. Conclusions Cathepsin K induces platelet dysfunction and affects signaling in breast cancer cells. Electronic supplementary material The online version of this article (doi:10.1186/s12885-016-2203-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Sheila Siqueira Andrade
- Departments of Gynecology of Universidade Federal de São Paulo, São Paulo, SP, 04024-002, Brazil. .,Charitable Association of Blood Collection - COLSAN, São Paulo, SP, 04080-006, Brazil. .,Department of Gynecology, Cellular Gynecology Laboratory, Universidade Federal de São Paulo, Rua Napoleão de Barros, 608, CEP 04024-002, São Paulo, Brazil.
| | - Iuri Estrada Gouvea
- Biophysics of Universidade Federal de São Paulo, São Paulo, SP, 04024-002, Brazil.
| | | | - Eloísa Dognani Castro
- Biochemistry of Universidade Federal de São Paulo, São Paulo, SP, 04024-002, Brazil.
| | - Cláudia A A de Paula
- Biochemistry of Universidade Federal de São Paulo, São Paulo, SP, 04024-002, Brazil.
| | - Debora Okamoto
- Biophysics of Universidade Federal de São Paulo, São Paulo, SP, 04024-002, Brazil.
| | - Lilian Oliveira
- Biophysics of Universidade Federal de São Paulo, São Paulo, SP, 04024-002, Brazil.
| | - Giovani Bravin Peres
- Biochemistry of Universidade Federal de São Paulo, São Paulo, SP, 04024-002, Brazil.
| | - Tatiana Ottaiano
- Biochemistry of Universidade Federal de São Paulo, São Paulo, SP, 04024-002, Brazil.
| | - Gil Facina
- Departments of Gynecology of Universidade Federal de São Paulo, São Paulo, SP, 04024-002, Brazil.
| | | | - Antonio Hugo J F M Campos
- Department of Pathology, AC Camargo Hospital Biobank, A C Camargo Cancer Center - Antonio Prudente Foundation, São Paulo, SP, 01509-010, Brazil.
| | | | - Maria Juliano
- Biophysics of Universidade Federal de São Paulo, São Paulo, SP, 04024-002, Brazil.
| | - Ismael D C G da Silva
- Departments of Gynecology of Universidade Federal de São Paulo, São Paulo, SP, 04024-002, Brazil.
| | - Maria Luiza V Oliva
- Biochemistry of Universidade Federal de São Paulo, São Paulo, SP, 04024-002, Brazil.
| | - Manoel J B C Girão
- Departments of Gynecology of Universidade Federal de São Paulo, São Paulo, SP, 04024-002, Brazil. .,Charitable Association of Blood Collection - COLSAN, São Paulo, SP, 04080-006, Brazil.
| |
Collapse
|
54
|
Liu YK, Ye J, Han QL, Tao R, Liu F, Wang W. Toxicity and bioactivity of cobalt nanoparticles on the monocytes. Orthop Surg 2016; 7:168-73. [PMID: 26033999 DOI: 10.1111/os.12180] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/09/2014] [Accepted: 04/07/2015] [Indexed: 11/28/2022] Open
Abstract
OBJECTIVE To explore the toxicity and biological activity of cobalt nanoparticles on the osteoclasts. Analyze the relationship between cobalt nanoparticles and osteolysis. METHODS Monocyte-macrophages (RAW 264.7) was cultured in vitro, osteoclast-like cells were induced by lipopolysaccharides (LPS). After RAW 264.7 was induced for 24 h, Methyl Thiazolium Tetrazolium (MTT) biological toxicity test of osteoclast-like cell was preceded using Cobalt nanoparticles (set 4 concentrations: 10, 20, 50, 100 μM) and cobalt chloride (set 4 concentrations: 10, 20, 50, 100 μM) at 2, 4, 8, 24 and 48 h respectively. The relative expression of mRNA of CA II and Cat K after RAW 264.7 induction was determined by Q-PCR. RESULTS mRNA relative expression of CA II, Cat K were reduced at multiple concentrations both cobalt nanoparticles and cobalt chloride, and was time and concentration dependent, cobalt nanoparticles are more significant than cobalt chloride group. But when the cobalt nanoparticles concentration is in 10-50 μM, the mRNA relative expression of CA II, Cat K increased. CONCLUSION Cobalt nanoparticles have biological toxicity. At multiple concentrations, the differentiation and proliferation of osteoclasts was inhibited, but when the concentration of cobalt nanoparticles is in 10-50 μM, it has been strengthened.
Collapse
Affiliation(s)
- Ya-ke Liu
- Institute of Orthopaedic Surgery, Affiliated Hospital of NanTong University, Nantong, Jiangsu, China
| | - Jun Ye
- Institute of Orthopaedic Surgery, Affiliated Hospital of NanTong University, Nantong, Jiangsu, China
| | - Qing-lin Han
- Institute of Orthopaedic Surgery, Affiliated Hospital of NanTong University, Nantong, Jiangsu, China
| | - Ran Tao
- Institute of Orthopaedic Surgery, Affiliated Hospital of NanTong University, Nantong, Jiangsu, China
| | - Fan Liu
- Institute of Orthopaedic Surgery, Affiliated Hospital of NanTong University, Nantong, Jiangsu, China
| | - Wei Wang
- Institute of Orthopaedic Surgery, Affiliated Hospital of NanTong University, Nantong, Jiangsu, China
| |
Collapse
|
55
|
Wang Y, Li R, Zheng Z, Yi H, Li Z. Identification of novel cathepsin K inhibitors using ligand-based virtual screening and structure-based docking. RSC Adv 2016. [DOI: 10.1039/c6ra14251f] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023] Open
Abstract
Compound 21 was identified as a cathepsin K (Cat K) inhibitor through pharmacophore virtual screening and molecular docking studies.
Collapse
Affiliation(s)
- Yali Wang
- Institute of Medicinal Biotechnology
- Chinese Academy of Medical Science and Peking Union Medical College
- Beijing 100050
- China
| | - Ruolan Li
- New Drug Research & Development Center
- North China Pharmaceutical Group Corporation
- Shijiazhuang 050015
- China
| | - Zhihui Zheng
- New Drug Research & Development Center
- North China Pharmaceutical Group Corporation
- Shijiazhuang 050015
- China
| | - Hong Yi
- Institute of Medicinal Biotechnology
- Chinese Academy of Medical Science and Peking Union Medical College
- Beijing 100050
- China
| | - Zhuorong Li
- Institute of Medicinal Biotechnology
- Chinese Academy of Medical Science and Peking Union Medical College
- Beijing 100050
- China
| |
Collapse
|
56
|
Verbovšek U, Van Noorden CJ, Lah TT. Complexity of cancer protease biology: Cathepsin K expression and function in cancer progression. Semin Cancer Biol 2015; 35:71-84. [DOI: 10.1016/j.semcancer.2015.08.010] [Citation(s) in RCA: 68] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2015] [Revised: 08/19/2015] [Accepted: 08/21/2015] [Indexed: 12/18/2022]
|
57
|
Bone biology, signaling pathways, and therapeutic targets for osteoporosis. Maturitas 2015; 82:245-55. [DOI: 10.1016/j.maturitas.2015.07.003] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2015] [Accepted: 07/06/2015] [Indexed: 01/16/2023]
|
58
|
Lecaille F, Lalmanach G, Andrault PM. Antimicrobial proteins and peptides in human lung diseases: A friend and foe partnership with host proteases. Biochimie 2015; 122:151-68. [PMID: 26341472 DOI: 10.1016/j.biochi.2015.08.014] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2015] [Accepted: 08/31/2015] [Indexed: 12/20/2022]
Abstract
Lung antimicrobial proteins and peptides (AMPs) are major sentinels of innate immunity by preventing microbial colonization and infection. Nevertheless bactericidal activity of AMPs against Gram-positive and Gram-negative bacteria is compromised in patients with chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and asthma. Evidence is accumulating that expression of harmful human serine proteases, matrix metalloproteases and cysteine cathepsins is markedely increased in these chronic lung diseases. The local imbalance between proteases and protease inhibitors compromises lung tissue integrity and function, by not only degrading extracellular matrix components, but also non-matrix proteins. Despite the fact that AMPs are somewhat resistant to proteolytic degradation, some human proteases cleave them efficiently and impair their antimicrobial potency. By contrast, certain AMPs may be effective as antiproteases. Host proteases participate in concert with bacterial proteases in the degradation of key innate immunity peptides/proteins and thus may play immunomodulatory activities during chronic lung diseases. In this context, the present review highlights the current knowledge and recent discoveries on the ability of host enzymes to interact with AMPs, providing a better understanding of the role of human proteases in innate host defense.
Collapse
Affiliation(s)
- Fabien Lecaille
- INSERM, UMR 1100, Pathologies Respiratoires: Protéolyse et Aérosolthérapie, Centre d'Etude des Pathologies Respiratoires, Equipe 2: « Mécanismes Protéolytiques dans l'Inflammation », Université François Rabelais, F-37032 Tours cedex, France.
| | - Gilles Lalmanach
- INSERM, UMR 1100, Pathologies Respiratoires: Protéolyse et Aérosolthérapie, Centre d'Etude des Pathologies Respiratoires, Equipe 2: « Mécanismes Protéolytiques dans l'Inflammation », Université François Rabelais, F-37032 Tours cedex, France
| | - Pierre-Marie Andrault
- INSERM, UMR 1100, Pathologies Respiratoires: Protéolyse et Aérosolthérapie, Centre d'Etude des Pathologies Respiratoires, Equipe 2: « Mécanismes Protéolytiques dans l'Inflammation », Université François Rabelais, F-37032 Tours cedex, France
| |
Collapse
|
59
|
Burton LJ, Smith BA, Smith BN, Loyd Q, Nagappan P, McKeithen D, Wilder CL, Platt MO, Hudson T, Odero-Marah VA. Muscadine grape skin extract can antagonize Snail-cathepsin L-mediated invasion, migration and osteoclastogenesis in prostate and breast cancer cells. Carcinogenesis 2015; 36:1019-27. [PMID: 26069256 PMCID: PMC4643647 DOI: 10.1093/carcin/bgv084] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2015] [Revised: 05/21/2015] [Accepted: 06/03/2015] [Indexed: 11/12/2022] Open
Abstract
To develop new and effective chemopreventive agents against bone metastasis, we assessed the effects of muscadine grape skin extract (MSKE), whose main bioactive component is anthocyanin, on bone turnover, using prostate and breast cancer cell models overexpressing Snail transcription factor. MSKE has been shown previously to promote apoptosis in prostate cancer cells without affecting normal prostate epithelial cells. Snail is overexpressed in prostate and breast cancer, and is associated with increased invasion, migration and bone turnover/osteoclastogenesis. Cathepsin L (CatL) is a cysteine cathepsin protease that is overexpressed in cancer and involved in bone turnover. Snail overexpression in prostate (LNCaP, ARCaP-E) and breast (MCF-7) cancer cells led to increased CatL expression/activity and phosphorylated STAT-3 (pSTAT-3), compared to Neo vector controls, while the reverse was observed in C4-2 (the aggressive subline of LNCaP) cells with Snail knockdown. Moreover, CatL expression was higher in prostate and breast tumor tissue compared to normal tissue. MSKE decreased Snail and pSTAT3 expression, and abrogated Snail-mediated CatL activity, migration and invasion. Additionally, Snail overexpression promoted osteoclastogenesis, which was significantly inhibited by the MSKE as effectively as Z-FY-CHO, a CatL-specific inhibitor, or osteoprotegerin, a receptor activator of nuclear factor kappa B ligand (RANKL) antagonist. Overall, these novel findings suggest that Snail regulation of CatL may occur via STAT-3 signaling and can be antagonized by MSKE, leading to decreased cell invasion, migration and bone turnover. Therefore, inhibition using a natural product such as MSKE could potentially be a promising bioactive compound for bone metastatic cancer.
Collapse
Affiliation(s)
- Liza J Burton
- Department of Biological Sciences, Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, GA 30314, USA Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA 30322, USA and Department of Medicine, Howard University, Washington, DC 20060, USA
| | - Basil A Smith
- Department of Biological Sciences, Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, GA 30314, USA Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA 30322, USA and Department of Medicine, Howard University, Washington, DC 20060, USA
| | - Bethany N Smith
- Department of Biological Sciences, Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, GA 30314, USA Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA 30322, USA and Department of Medicine, Howard University, Washington, DC 20060, USA
| | - Quentin Loyd
- Department of Biological Sciences, Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, GA 30314, USA Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA 30322, USA and Department of Medicine, Howard University, Washington, DC 20060, USA
| | - Peri Nagappan
- Department of Biological Sciences, Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, GA 30314, USA Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA 30322, USA and Department of Medicine, Howard University, Washington, DC 20060, USA
| | - Danielle McKeithen
- Department of Biological Sciences, Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, GA 30314, USA Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA 30322, USA and Department of Medicine, Howard University, Washington, DC 20060, USA
| | - Catera L Wilder
- Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA 30322, USA and
| | - Manu O Platt
- Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA 30322, USA and
| | - Tamaro Hudson
- Department of Medicine, Howard University, Washington, DC 20060, USA
| | - Valerie A Odero-Marah
- Department of Biological Sciences, Center for Cancer Research and Therapeutic Development, Clark Atlanta University, Atlanta, GA 30314, USA Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA 30322, USA and Department of Medicine, Howard University, Washington, DC 20060, USA
| |
Collapse
|
60
|
Kyostio-Moore S, Piraino S, Berthelette P, Moran N, Serriello J, Bendele A, Sookdeo C, Nambiar B, Ewing P, Armentano D, Matthews GL. Overexpression of cystatin C in synovium does not reduce synovitis or cartilage degradation in established osteoarthritis. Arthritis Res Ther 2015; 17:5. [PMID: 25592743 PMCID: PMC4350912 DOI: 10.1186/s13075-015-0519-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2014] [Accepted: 01/07/2015] [Indexed: 11/13/2022] Open
Abstract
Introduction Cathepsin K (catK) expression is increased in cartilage, bone and synovium during osteoarthritis (OA). To study the role of catK expression and elevated cathepsin activity in the synovium on cartilage destruction in established OA, we overexpressed cystatin C (cysC), a natural cysteine protease inhibitor, in the synovium of rabbit OA joints. Methods The ability of cysC to inhibit activity of cathepsins in rabbit OA synovium lysates was tested in vitro using protease activity assay. In vivo, the tissue localization of recombinant adeno-associated virus (rAAV) with LacZ gene after intra-articular injection was determined by β-galactosidase staining of rabbit joints 4 weeks later. To inhibit cathepsin activity in the synovium, a rAAV2-encoding cysC was delivered intra-articularly into rabbit joints 4 weeks after OA was induced by anterior cruciate ligament transection (ACLT). Seven weeks postinjection, endogenous catK and cysC levels as well as the vector-derived cysC expression in the synovium of normal and OA joints were examined by RNA quantification. Synovial cathepsin activity and catK, catB and catL protein levels were determined by activity and Western blot analyses, respectively. Synovitis and cartilage degradation were evaluated by histopathological scoring. Results In vitro, the ability of cysC to efficiently inhibit activity of purified catK and OA-induced cathepsins in rabbit synovial lysates was demonstrated. In vivo, the intra-articular delivery of rAAV2/LacZ showed transduction of mostly synovium. Induction of OA in rabbit joints resulted in fourfold increase in catK mRNA compared to sham controls while no change was detected in endogenous cysC mRNA levels in the synovium. Protein levels for catK, catB and catL were also increased in the synovium with a concomitant fourfold increase in cathepsin activity. Joints treated with rAAV2/cysC showed both detection of vector genomes and vector-derived cysC transcripts in the synovium. Production of functional cysC by the vector was demonstrated by complete block of cathepsin activity in the synovium. However, this did not decrease synovitis, bone sclerosis or progression of cartilage degradation. Conclusions Increased production of natural cathepsin inhibitor, cysC, in OA synovium does not alleviate synovitis or cartilage pathology during a preexisting OA.
Collapse
Affiliation(s)
- Sirkka Kyostio-Moore
- Gene Therapy, Genzyme, a Sanofi Company, 49 New York Avenue, Framingham, MA, USA.
| | - Susan Piraino
- Gene Therapy, Genzyme, a Sanofi Company, 49 New York Avenue, Framingham, MA, USA.
| | - Patricia Berthelette
- Gene Therapy, Genzyme, a Sanofi Company, 49 New York Avenue, Framingham, MA, USA.
| | - Nance Moran
- Orthopaedic Research, Genzyme, a Sanofi Company, 49 New York Avenue, Framingham, MA, USA.
| | - Joseph Serriello
- Orthopaedic Research, Genzyme, a Sanofi Company, 49 New York Avenue, Framingham, MA, USA.
| | | | - Cathleen Sookdeo
- Gene Therapy, Genzyme, a Sanofi Company, 49 New York Avenue, Framingham, MA, USA.
| | - Bindu Nambiar
- Gene Therapy, Genzyme, a Sanofi Company, 49 New York Avenue, Framingham, MA, USA.
| | - Patty Ewing
- Pathology, Genzyme, a Sanofi Company, 5 Mountain Road, Framingham, MA, USA.
| | - Donna Armentano
- Gene Therapy, Genzyme, a Sanofi Company, 49 New York Avenue, Framingham, MA, USA.
| | - Gloria L Matthews
- Orthopaedic Research, Genzyme, a Sanofi Company, 49 New York Avenue, Framingham, MA, USA.
| |
Collapse
|
61
|
[Cathepsin K antagonists: preclinical and clinical data]. Wien Med Wochenschr 2015; 165:65-70. [PMID: 25572547 DOI: 10.1007/s10354-014-0336-3] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2014] [Accepted: 11/20/2014] [Indexed: 10/24/2022]
Abstract
Cathepsin K, a cysteine protease, is an essential enzyme in degradation of collagen type I. Since cathepsin K is relatively specific to osteoclasts, it represents a promising candidate for drug development. In the past decades, efforts have been made in developing highly potent, selective and orally applicable cathepsin K inhibitors. In contrast to balicatib and relacatib, whose drug development programmes were stopped due to cutaneous side-effects related to limited drug specificity, the more specific cathepsin K inhibitors odanacatib (ODN) and ONO-5334 have entered clinical trials. Odanacatib progressively increases bone mineral density (BMD) and decreases bone resorption markers in postmenopausal women with low BMD. Its clinical efficacy and safety was confirmed by several clinical studies but indicates that odanacatib is characterized by a resolution-of-effect with increases in bone resorption and rapid decreases in BMD following treatment discontinuation. A phase III fracture prevention study in postmenopausal women with osteoporosis is currently in the final phase.
Collapse
|
62
|
Abstract
Despite the availability of efficacious treatments for fracture reduction in patients with osteoporosis, there are still unmet needs requiring a broader range of therapeutics. In particular, agents that are capable of replacing already lost bone and that also drastically reduce the risk of non-vertebral fractures are needed. Studies of rare bone diseases in humans and animal genetics have identified targets in bone cells for the development of therapies for osteoporosis with novel mechanisms of action. Here, we review these new developments, with emphasis on inhibitors of cathepsin K in osteoclasts and sclerostin in osteocytes, which are currently studied in phase 3 clinical trials.
Collapse
Affiliation(s)
| | - Socrates E Papapoulos
- Center for Bone Quality, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.
| |
Collapse
|
63
|
Tezvergil-Mutluay A, Agee KA, Mazzoni A, Carvalho RM, Carrilho M, Tersariol IL, Nascimento FD, Imazato S, Tjäderhane L, Breschi L, Tay FR, Pashley DH. Can quaternary ammonium methacrylates inhibit matrix MMPs and cathepsins? Dent Mater 2014; 31:e25-32. [PMID: 25467953 DOI: 10.1016/j.dental.2014.10.006] [Citation(s) in RCA: 43] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2014] [Accepted: 10/31/2014] [Indexed: 10/24/2022]
Abstract
OBJECTIVE Dentin matrices release ICTP and CTX fragments during collagen degradation. ICTP fragments are known to be produced by MMPs. CTX fragments are thought to come from cathepsin K activity. The purpose of this study was to determine if quaternary methacrylates (QAMs) can inhibit matrix MMPs and cathepsins. METHODS Dentin beams were demineralizated, and dried to constant weight. Beams were incubated with rh-cathepsin B, K, L or S for 24h at pH 7.4 to identify which cathepsins release CTX at neutral pH. Beams were dipped in ATA, an antimicrobial QAM to determine if it can inhibit dentin matrix proteases. Other beams were dipped in another QAM (MDPB) to determine if it produced similar inhibition of dentin proteases. RESULTS Only beams incubated with cathepsin K lost more dry mass than the controls and released CTX. Dentin beams dipped in ATA and incubated for 1 week at pH 7.4, showed a concentration-dependent reduction in weight-loss. There was no change in ICTP release from control values, meaning that ATA did not inhibit MMPs. Media concentrations of CTX fell significantly at 15wt% ATA indicating that ATA inhibits capthesins. Beams dipped in increasing concentrations of MDPB lost progressively less mass, showing that MDPB is a protease-inhibitor. ICTP released from controls or beams exposed to low concentrations were the same, while 5 or 10% MDPB significantly lowered ICTP production. CTX levels were strongly inhibited by 2.5-10% MDPB, indicating that MDPB is a potent inhibitor of both MMPs and cathepsin K. SIGNIFICANCE CTX seems to be released from dentin matrix only by cathepsin K. MMPs and cathepsin K and B may all contribute to matrix degradation.
Collapse
Affiliation(s)
- Arzu Tezvergil-Mutluay
- Adhesive Dentistry Research Group, Institute of Dentistry, University of Turku, Turku, Finland
| | - Kelli A Agee
- Department of Oral Biology, College of Dental Medicine, Georgia Regents University, Augusta, GA, USA
| | | | - Ricardo M Carvalho
- Department of Oral Science, School of Dentistry, University of British Columbia, Vancouver, British Columbia, Canada
| | - Marcela Carrilho
- UNIBAN (University Bandeirante Anhanguera), Biomaterials Research Group, Sao Paulo, Brazil
| | - Ivarne L Tersariol
- Centro Interdisciplinar de Investigacão Bioquimica, University of Mogi das Cruzes, Mogi das cruzes, Brazil; Department of Biochemistry, Federal University São Paulo, Brazil
| | | | - Satoshi Imazato
- Osaka University Graduate School of Dentistry, Department of Biomaterials Science, Osaka, Japan
| | - Leo Tjäderhane
- Institute of Dentistry, University of Oulu, Oulu University Hospital, Oulu, Finland; Institute of Dentistry, University of Turku, Turku, Finland
| | - Lorenzo Breschi
- Department of SAU&FAL, University of Bologna, Bologna, Italy; UNIBAN (University Bandeirante Anhanguera), Biomaterials Research Group, Sao Paulo, Brazil
| | - Franklin R Tay
- Department of Oral Biology, College of Dental Medicine, Georgia Regents University, Augusta, GA, USA
| | - David H Pashley
- Department of Oral Biology, College of Dental Medicine, Georgia Regents University, Augusta, GA, USA.
| |
Collapse
|
64
|
Lemaire PA, Huang L, Zhuo Y, Lu J, Bahnck C, Stachel SJ, Carroll SS, Duong LT. Chondroitin sulfate promotes activation of cathepsin K. J Biol Chem 2014; 289:21562-72. [PMID: 24958728 DOI: 10.1074/jbc.m114.559898] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Cathepsin K (CatK), a major lysosomal collagenase produced by osteoclasts, plays an important role in bone resorption. Evidence exists that the collagenase activity of CatK is promoted by chondroitin sulfate (CS), a sulfated glycosaminoglycan. This study examines the role of CS in facilitating CatK activation. We have demonstrated that chondroitin 4-sulfate (C4-S) promotes autoprocessing of the pro-domain of CatK at pH ≤ 5, leading to a fully matured enzyme with collagenase and peptidase activities. We present evidence to demonstrate this autoactivation process is a trans-activation event that is efficiently inhibited by both the covalent cysteine protease inhibitor E-64 and the reversible selective CatK inhibitor L-006,235. During bone resorption, CatK and C4-S are co-localized at the ruffled border between osteoclast bone interface, supporting the proposal that CatK activation is accomplished through the combined action of the acidic environment together with the presence of a high concentration of C4-S. Formation of a multimeric complex between C4-S and pro-CatK has been speculated to accelerate CatK autoactivation and promote efficient collagen degradation. Together, these results demonstrate that CS plays an important role in contributing to the enhanced efficiency of CatK collagenase activity in vivo.
Collapse
Affiliation(s)
| | | | | | - Jun Lu
- Structural Chemistry, and
| | | | - Shawn J Stachel
- Medicinal Chemistry, Merck Research Laboratories, West Point, Pennsylvania 19486
| | | | | |
Collapse
|
65
|
Hua Y, Nair S. Proteases in cardiometabolic diseases: Pathophysiology, molecular mechanisms and clinical applications. Biochim Biophys Acta Mol Basis Dis 2014; 1852:195-208. [PMID: 24815358 DOI: 10.1016/j.bbadis.2014.04.032] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2014] [Revised: 04/25/2014] [Accepted: 04/30/2014] [Indexed: 12/21/2022]
Abstract
Cardiovascular disease is the leading cause of death in the U.S. and other developed countries. Metabolic syndrome, including obesity, diabetes/insulin resistance, hypertension and dyslipidemia is a major threat for public health in the modern society. It is well established that metabolic syndrome contributes to the development of cardiovascular disease collective called as cardiometabolic disease. Despite documented studies in the research field of cardiometabolic disease, the underlying mechanisms are far from clear. Proteases are enzymes that break down proteins, many of which have been implicated in various diseases including cardiac disease. Matrix metalloproteinase (MMP), calpain, cathepsin and caspase are among the major proteases involved in cardiac remodeling. Recent studies have also implicated proteases in the pathogenesis of cardiometabolic disease. Elevated expression and activities of proteases in atherosclerosis, coronary heart disease, obesity/insulin-associated heart disease as well as hypertensive heart disease have been documented. Furthermore, transgenic animals that are deficient in or over-express proteases allow scientists to understand the causal relationship between proteases and cardiometabolic disease. Mechanistically, MMPs and cathepsins exert their effect on cardiometabolic diseases mainly through modifying the extracellular matrix. However, MMP and cathepsin are also reported to affect intracellular proteins, by which they contribute to the development of cardiometabolic diseases. On the other hand, activation of calpain and caspases has been shown to influence intracellular signaling cascade including the NF-κB and apoptosis pathways. Clinically, proteases are reported to function as biomarkers of cardiometabolic diseases. More importantly, the inhibitors of proteases are credited with beneficial cardiometabolic profile, although the exact molecular mechanisms underlying these salutary effects are still under investigation. A better understanding of the role of MMPs, cathepsins, calpains and caspases in cardiometabolic diseases process may yield novel therapeutic targets for treating or controlling these diseases. This article is part of a Special Issue entitled: Autophagy and protein quality control in cardiometabolic diseases.
Collapse
Affiliation(s)
- Yinan Hua
- Center for Cardiovascular Research and Alternative Medicine, University of Wyoming, School of Pharmacy, College of Health Sciences, Laramie, WY 82071, USA.
| | - Sreejayan Nair
- Center for Cardiovascular Research and Alternative Medicine, University of Wyoming, School of Pharmacy, College of Health Sciences, Laramie, WY 82071, USA.
| |
Collapse
|
66
|
Novinec M, Lenarčič B. Cathepsin K: a unique collagenolytic cysteine peptidase. Biol Chem 2014; 394:1163-79. [PMID: 23629523 DOI: 10.1515/hsz-2013-0134] [Citation(s) in RCA: 92] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2013] [Accepted: 04/24/2013] [Indexed: 11/15/2022]
Abstract
Cathepsin K has emerged as a promising target for the treatment of osteoporosis in recent years. Initially identified as a papain-like cysteine peptidase expressed in high levels in osteoclasts, the important role of this enzyme in bone metabolism was highlighted by the finding that mutations in the CTSK gene cause the rare recessive disorder pycnodysostosis, which is characterized by severe bone anomalies. At the molecular level, the physiological role of cathepsin K is reflected by its unique cleavage pattern of type I collagen molecules, which is fundamentally different from that of other endogenous collagenases. Several cathepsin K inhibitors have been developed to reduce the excessive bone matrix degradation associated with osteoporosis, with the frontrunner odanacatib about to successfully conclude Phase 3 clinical trials. Apart from osteoclasts, cathepsin K is expressed in different cell types throughout the body and is involved in processes of adipogenesis, thyroxine liberation and peptide hormone regulation. Elevated activity of cathepsin K has been associated with arthritis, atherosclerosis, obesity, schizophrenia, and tumor metastasis. Accordingly, its activity is tightly regulated via multiple mechanisms, including competitive inhibition by endogenous macromolecular inhibitors and allosteric regulation by glycosaminoglycans. This review provides a state-of-the-art description of the activity of cathepsin K at the molecular level, its biological functions and the mechanisms involved in its regulation.
Collapse
Affiliation(s)
- Marko Novinec
- Department of Chemistry and Biochemistry, Faculty of Chemistry and Chemical Technology, University of Ljubljana, SI-1000 Ljubljana, Slovenia.
| | | |
Collapse
|
67
|
Sciani JM, Antoniazzi MM, Neves ADC, Pimenta DC. Cathepsin B/X is secreted by Echinometra lucunter sea urchin spines, a structure rich in granular cells and toxins. J Venom Anim Toxins Incl Trop Dis 2013; 19:33. [PMID: 24341625 PMCID: PMC3880103 DOI: 10.1186/1678-9199-19-33] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2013] [Accepted: 12/09/2013] [Indexed: 11/22/2022] Open
Abstract
Background Echinometra lucunter is a common American sea urchin responsible for the majority of the marine accidents in Brazil. Although not lethal, these accidents are reported to be extremely painful. Recently, our group described the presence of toxins in its spines that contribute to the pathological reactions. Additionally, we have observed that the E. lucunter spines can regenerate when broken. In the present work we evaluated the enzymatic activities of sea urchin spine extracts in order to identify an enzyme that could contribute not only to the toxicity, but also participate in the spine growth and regeneration. Results The spine aqueous extract was tested for peptidase activity, with synthetic substrates, in the presence and absence of inhibitors and activators. For proper enzyme classification, the FRET-substrate cleavage pattern, pH-dependency activity and Western-blot analyses were performed. The spine extract was able to cleave Z-R-MCA and Abz-GIVRAK(Dnp)-OH following pre-incubation with DTT, and was inhibited by E-64. Furthermore, the double-peaked pH curve (5 and 7) and the cleavage site proportion (4:6, R↓A:A↓K) indicate the presence of both mono and dicarboxypeptidase activities. Moreover, in Western-blot analysis, the spine extract was positive for anti-cathepsin B antibody. Conclusions E. lucunter spines extracts presented a cysteine peptidase activity that was identified as cathepsin B/X that would participate in the remodeling and growth processes of the spine, as well as in the inflammatory response to the accident.
Collapse
Affiliation(s)
| | | | | | - Daniel Carvalho Pimenta
- Laboratory of Biochemistry and Biophysics, Butantan Institute, São Paulo, São Paulo State, Brazil.
| |
Collapse
|
68
|
Brignull LM, Czimmerer Z, Saidi H, Daniel B, Villela I, Bartlett NW, Johnston SL, Meira LB, Nagy L, Nohturfft A. Reprogramming of lysosomal gene expression by interleukin-4 and Stat6. BMC Genomics 2013; 14:853. [PMID: 24314139 PMCID: PMC3880092 DOI: 10.1186/1471-2164-14-853] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2013] [Accepted: 11/26/2013] [Indexed: 01/05/2023] Open
Abstract
Background Lysosomes play important roles in multiple aspects of physiology, but the problem of how the transcription of lysosomal genes is coordinated remains incompletely understood. The goal of this study was to illuminate the physiological contexts in which lysosomal genes are coordinately regulated and to identify transcription factors involved in this control. Results As transcription factors and their target genes are often co-regulated, we performed meta-analyses of array-based expression data to identify regulators whose mRNA profiles are highly correlated with those of a core set of lysosomal genes. Among the ~50 transcription factors that rank highest by this measure, 65% are involved in differentiation or development, and 22% have been implicated in interferon signaling. The most strongly correlated candidate was Stat6, a factor commonly activated by interleukin-4 (IL-4) or IL-13. Publicly available chromatin immunoprecipitation (ChIP) data from alternatively activated mouse macrophages show that lysosomal genes are overrepresented among Stat6-bound targets. Quantification of RNA from wild-type and Stat6-deficient cells indicates that Stat6 promotes the expression of over 100 lysosomal genes, including hydrolases, subunits of the vacuolar H+ ATPase and trafficking factors. While IL-4 inhibits and activates different sets of lysosomal genes, Stat6 mediates only the activating effects of IL-4, by promoting increased expression and by neutralizing undefined inhibitory signals induced by IL-4. Conclusions The current data establish Stat6 as a broadly acting regulator of lysosomal gene expression in mouse macrophages. Other regulators whose expression correlates with lysosomal genes suggest that lysosome function is frequently re-programmed during differentiation, development and interferon signaling.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Axel Nohturfft
- Division of Biomedical Sciences, Molecular and Metabolic Signaling Centre, St, George's University of London, Cranmer Terrace, London SW17 0RE, UK.
| |
Collapse
|
69
|
Dumas JE, Platt MO. Systematic optimization of multiplex zymography protocol to detect active cathepsins K, L, S, and V in healthy and diseased tissue: compromise among limits of detection, reduced time, and resources. Mol Biotechnol 2013; 54:1038-47. [PMID: 23532386 DOI: 10.1007/s12033-013-9658-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Cysteine cathepsins are a family of proteases identified in cancer, atherosclerosis, osteoporosis, arthritis, and a number of other diseases. As this number continues to rise, so does the need for low cost, broad use quantitative assays to detect their activity and can be translated to the clinic in the hospital or in low resource settings. Multiplex cathepsin zymography is one such assay that detects subnanomolar levels of active cathepsins K, L, S, and V in cell or tissue preparations observed as clear bands of proteolytic activity after gelatin substrate SDS-PAGE with conditions optimal for cathepsin renaturing and activity. Densitometric analysis of the zymogram provides quantitative information from this low cost assay. After systematic modifications to optimize cathepsin zymography, we describe reduced electrophoresis time from 2 h to 10 min, incubation assay time from overnight to 4 h, and reduced minimal tissue protein necessary while maintaining sensitive detection limits; an evaluation of the pros and cons of each modification is also included. We further describe image acquisition by Smartphone camera, export to Matlab, and densitometric analysis code to quantify and report cathepsin activity, adding portability and replacing large scale, darkbox imaging equipment that could be cost prohibitive in limited resource settings.
Collapse
Affiliation(s)
- Jerald E Dumas
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, 315 Ferst Dr. Suite 1308, Atlanta, GA 30332, USA
| | | |
Collapse
|
70
|
Sun S, Karsdal M, Bay-Jensen A, Sørensen M, Zheng Q, Dziegiel M, Maksymowych W, Henriksen K. The development and characterization of an ELISA specifically detecting the active form of cathepsin K. Clin Biochem 2013; 46:1601-6. [DOI: 10.1016/j.clinbiochem.2013.04.012] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2013] [Revised: 03/19/2013] [Accepted: 04/13/2013] [Indexed: 11/28/2022]
|
71
|
Lewiecki EM, Adler RA, Bilezikian JP, Bouxsein ML, Marcus R, McClung MR, Miller PD, Tanner SB, Randall S. Osteoporosis update from the 2012 Santa Fe Bone Symposium. J Clin Densitom 2013; 16:584-600. [PMID: 23419827 DOI: 10.1016/j.jocd.2013.01.001] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/12/2012] [Accepted: 01/14/2013] [Indexed: 01/30/2023]
Abstract
The core of the 2012 Santa Fe Bone Symposium consisted of plenary presentations on new developments in the fields of osteoporosis and metabolic bone disease, with a focus on current and future implications for patient care. These were complemented by oral abstracts, interactive discussions of challenging cases, a debate on benefits and risks of long-term bisphosphonate therapy, and a panel discussion of controversial issues in the management of osteoporosis. Other topics included a review of the most important scientific publications in the past year, new and emerging therapy for osteoporosis, the benefits and limitations of clinical practice guidelines in the care of individual patients, the effects of metallic elements on skeletal health, clinical applications of bone turnover markers, an engineering perspective of skeletal health and disease, and an update on the role of the International Society for Clinical Densitometry in education, certification, accreditation, and advocacy for high-quality bone density testing. The symposium was highlighted by an inaugural presentation of "2 Million 2 Many," a national campaign of the National Bone Health Alliance to increase awareness of osteoporosis.
Collapse
Affiliation(s)
- E Michael Lewiecki
- New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
72
|
Madsen DH, Leonard D, Masedunskas A, Moyer A, Jürgensen HJ, Peters DE, Amornphimoltham P, Selvaraj A, Yamada SS, Brenner DA, Burgdorf S, Engelholm LH, Behrendt N, Holmbeck K, Weigert R, Bugge TH. M2-like macrophages are responsible for collagen degradation through a mannose receptor-mediated pathway. J Cell Biol 2013; 202:951-66. [PMID: 24019537 PMCID: PMC3776354 DOI: 10.1083/jcb.201301081] [Citation(s) in RCA: 239] [Impact Index Per Article: 21.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2013] [Accepted: 07/31/2013] [Indexed: 02/07/2023] Open
Abstract
Tissue remodeling processes critically depend on the timely removal and remodeling of preexisting collagen scaffolds. Nevertheless, many aspects related to the turnover of this abundant extracellular matrix component in vivo are still incompletely understood. We therefore took advantage of recent advances in optical imaging to develop an assay to visualize collagen turnover in situ and identify cell types and molecules involved in this process. Collagen introduced into the dermis of mice underwent cellular endocytosis in a partially matrix metalloproteinase-dependent manner and was subsequently routed to lysosomes for complete degradation. Collagen uptake was predominantly executed by a quantitatively minor population of M2-like macrophages, whereas more abundant Col1a1-expressing fibroblasts and Cx3cr1-expressing macrophages internalized collagen at lower levels. Genetic ablation of the collagen receptors mannose receptor (Mrc1) and urokinase plasminogen activator receptor-associated protein (Endo180 and Mrc2) impaired this intracellular collagen degradation pathway. This study demonstrates the importance of receptor-mediated cellular uptake to collagen turnover in vivo and identifies a key role of M2-like macrophages in this process.
Collapse
MESH Headings
- Animals
- Apoptosis
- Blotting, Western
- CX3C Chemokine Receptor 1
- Cell Proliferation
- Cells, Cultured
- Collagen/metabolism
- Collagen Type I/physiology
- Collagen Type I, alpha 1 Chain
- Endocytosis/physiology
- Female
- Fibroblasts/cytology
- Fibroblasts/metabolism
- Green Fluorescent Proteins/genetics
- Green Fluorescent Proteins/metabolism
- Humans
- Immunoenzyme Techniques
- Lysosomes/metabolism
- Macrophages/cytology
- Macrophages/metabolism
- Membrane Glycoproteins/physiology
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Mice, Transgenic
- RNA, Messenger/genetics
- Real-Time Polymerase Chain Reaction
- Receptors, Cell Surface/physiology
- Receptors, Chemokine/physiology
- Receptors, Immunologic
- Reverse Transcriptase Polymerase Chain Reaction
- Signal Transduction
Collapse
Affiliation(s)
- Daniel H. Madsen
- Proteases and Tissue Remodeling Section and Intracellular Membrane Trafficking Unit, Oral and Pharyngeal Cancer Branch, and Matrix Metalloproteinase Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892
- The Finsen Laboratory, Rigshospitalet/Biotech Research and Innovation Centre, University of Copenhagen, 2100 Copenhagen, Denmark
| | - Daniel Leonard
- Proteases and Tissue Remodeling Section and Intracellular Membrane Trafficking Unit, Oral and Pharyngeal Cancer Branch, and Matrix Metalloproteinase Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892
| | - Andrius Masedunskas
- Proteases and Tissue Remodeling Section and Intracellular Membrane Trafficking Unit, Oral and Pharyngeal Cancer Branch, and Matrix Metalloproteinase Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892
| | - Amanda Moyer
- Proteases and Tissue Remodeling Section and Intracellular Membrane Trafficking Unit, Oral and Pharyngeal Cancer Branch, and Matrix Metalloproteinase Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892
| | - Henrik Jessen Jürgensen
- Proteases and Tissue Remodeling Section and Intracellular Membrane Trafficking Unit, Oral and Pharyngeal Cancer Branch, and Matrix Metalloproteinase Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892
- The Finsen Laboratory, Rigshospitalet/Biotech Research and Innovation Centre, University of Copenhagen, 2100 Copenhagen, Denmark
| | - Diane E. Peters
- Proteases and Tissue Remodeling Section and Intracellular Membrane Trafficking Unit, Oral and Pharyngeal Cancer Branch, and Matrix Metalloproteinase Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892
- Program of Pharmacology and Experimental Therapeutics, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA 02111
| | - Panomwat Amornphimoltham
- Proteases and Tissue Remodeling Section and Intracellular Membrane Trafficking Unit, Oral and Pharyngeal Cancer Branch, and Matrix Metalloproteinase Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892
| | - Arul Selvaraj
- Proteases and Tissue Remodeling Section and Intracellular Membrane Trafficking Unit, Oral and Pharyngeal Cancer Branch, and Matrix Metalloproteinase Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892
| | - Susan S. Yamada
- Proteases and Tissue Remodeling Section and Intracellular Membrane Trafficking Unit, Oral and Pharyngeal Cancer Branch, and Matrix Metalloproteinase Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892
| | - David A. Brenner
- Department of Medicine, University of California, San Diego, La Jolla, CA 92093
| | - Sven Burgdorf
- Life and Medical Sciences Institute, University of Bonn, 53115 Bonn, Germany
| | - Lars H. Engelholm
- The Finsen Laboratory, Rigshospitalet/Biotech Research and Innovation Centre, University of Copenhagen, 2100 Copenhagen, Denmark
| | - Niels Behrendt
- The Finsen Laboratory, Rigshospitalet/Biotech Research and Innovation Centre, University of Copenhagen, 2100 Copenhagen, Denmark
| | - Kenn Holmbeck
- Proteases and Tissue Remodeling Section and Intracellular Membrane Trafficking Unit, Oral and Pharyngeal Cancer Branch, and Matrix Metalloproteinase Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892
| | - Roberto Weigert
- Proteases and Tissue Remodeling Section and Intracellular Membrane Trafficking Unit, Oral and Pharyngeal Cancer Branch, and Matrix Metalloproteinase Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892
| | - Thomas H. Bugge
- Proteases and Tissue Remodeling Section and Intracellular Membrane Trafficking Unit, Oral and Pharyngeal Cancer Branch, and Matrix Metalloproteinase Section, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20892
| |
Collapse
|
73
|
Emmott AA, Mort JS. Efficient processing of procathepsin K to the mature form. Protein Expr Purif 2013; 91:37-41. [DOI: 10.1016/j.pep.2013.06.012] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2013] [Revised: 06/06/2013] [Accepted: 06/25/2013] [Indexed: 11/16/2022]
|
74
|
Duong LT. Inhibition of cathepsin K: blocking osteoclast bone resorption and more. ACTA ACUST UNITED AC 2013. [DOI: 10.1038/bonekey.2013.130] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
75
|
|
76
|
Corvo I, O'Donoghue AJ, Pastro L, Pi-Denis N, Eroy-Reveles A, Roche L, McKerrow JH, Dalton JP, Craik CS, Caffrey CR, Tort JF. Dissecting the active site of the collagenolytic cathepsin L3 protease of the invasive stage of Fasciola hepatica. PLoS Negl Trop Dis 2013; 7:e2269. [PMID: 23875031 PMCID: PMC3708847 DOI: 10.1371/journal.pntd.0002269] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2013] [Accepted: 03/23/2013] [Indexed: 11/18/2022] Open
Abstract
Background A family of secreted cathepsin L proteases with differential activities is essential for host colonization and survival in the parasitic flatworm Fasciola hepatica. While the blood feeding adult secretes predominantly FheCL1, an enzyme with a strong preference for Leu at the S2 pocket of the active site, the infective stage produces FheCL3, a unique enzyme with collagenolytic activity that favours Pro at P2. Methodology/Principal Findings Using a novel unbiased multiplex substrate profiling and mass spectrometry methodology (MSP-MS), we compared the preferences of FheCL1 and FheCL3 along the complete active site cleft and confirm that while the S2 imposes the greatest influence on substrate selectivity, preferences can be indicated on other active site subsites. Notably, we discovered that the activity of FheCL1 and FheCL3 enzymes is very different, sharing only 50% of the cleavage sites, supporting the idea of functional specialization. We generated variants of FheCL1 and FheCL3 with S2 and S3 residues by mutagenesis and evaluated their substrate specificity using positional scanning synthetic combinatorial libraries (PS-SCL). Besides the rare P2 Pro preference, FheCL3 showed a distinctive specificity at the S3 pocket, accommodating preferentially the small Gly residue. Both P2 Pro and P3 Gly preferences were strongly reduced when Trp67 of FheCL3 was replaced by Leu, rendering the enzyme incapable of digesting collagen. In contrast, the inverse Leu67Trp substitution in FheCL1 only slightly reduced its Leu preference and improved Pro acceptance in P2, but greatly increased accommodation of Gly at S3. Conclusions/Significance These data reveal the significance of S2 and S3 interactions in substrate binding emphasizing the role for residue 67 in modulating both sites, providing a plausible explanation for the FheCL3 collagenolytic activity essential to host invasion. The unique specificity of FheCL3 could be exploited in the design of specific inhibitors selectively directed to specific infective stage parasite proteinases. The flatworm Fasciola hepatica is responsible for fasciolosis, one of the most common parasitic diseases of livestock worldwide, with increased incidence of human cases. When contaminated plants are ingested, infective larvae are released and transverse the gut wall before migrating to the bile ducts within the liver. Migrating liver flukes erode host tissue while adults feed on blood and they mature and release thousands of eggs. Several developmentally-regulated cathepsin L like proteolytic enzymes (FheCLs) are essential to the migrating and feeding processes. Despite being similar in structure and sequence these enzymes show specialization attacking preferentially different substrates and taking part in the diverse process of invasion, immune evasion and feeding. Our analyses reveal unique differences in activity between the major infective juvenile (FheCL3) and adult (FheCL1) enzymes, and demonstrate that the juvenile enzyme has a particular active site that allows it to degrade collagen, the main component of connective tissues. We demonstrate that a single position on the active site, residue 67, is essential to this collagenolytic activity critical for parasite invasion.
Collapse
Affiliation(s)
- Ileana Corvo
- Departamento de Genética, Facultad de Medicina, Universidad de la República, UDELAR, Montevideo, Uruguay
| | - Anthony J. O'Donoghue
- Department of Pharmaceutical Chemistry, Pharmacology, and Biochemistry and Biophysics, University of California, San Francisco, California, United States of America
| | - Lucía Pastro
- Departamento de Genética, Facultad de Medicina, Universidad de la República, UDELAR, Montevideo, Uruguay
- Laboratorio de Interacciones Moleculares, Facultad de Ciencias, Universidad de la República, UDELAR, Montevideo, Uruguay
| | - Natalia Pi-Denis
- Departamento de Genética, Facultad de Medicina, Universidad de la República, UDELAR, Montevideo, Uruguay
| | - Alegra Eroy-Reveles
- Department of Chemistry and Biochemistry, San Francisco State University, San Francisco, California, United States of America
| | - Leda Roche
- Departamento de Genética, Facultad de Medicina, Universidad de la República, UDELAR, Montevideo, Uruguay
| | - James H. McKerrow
- Center for Discovery and Innovation in Parasitic Diseases, Department of Pathology, University of California, San Francisco, California, United States of America
| | - John P. Dalton
- Institute of Parasitology, McGill University, Quebec, Canada
| | - Charles S. Craik
- Department of Pharmaceutical Chemistry, Pharmacology, and Biochemistry and Biophysics, University of California, San Francisco, California, United States of America
| | - Conor R. Caffrey
- Center for Discovery and Innovation in Parasitic Diseases, Department of Pathology, University of California, San Francisco, California, United States of America
| | - José F. Tort
- Departamento de Genética, Facultad de Medicina, Universidad de la República, UDELAR, Montevideo, Uruguay
- * E-mail:
| |
Collapse
|
77
|
Erlandsson MC, Svensson MD, Jonsson IM, Bian L, Ambartsumian N, Andersson S, Peng Z, Vääräniemi J, Ohlsson C, Andersson KME, Bokarewa MI. Expression of metastasin S100A4 is essential for bone resorption and regulates osteoclast function. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH 2013; 1833:2653-2663. [PMID: 23830916 DOI: 10.1016/j.bbamcr.2013.06.020] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/21/2013] [Revised: 05/31/2013] [Accepted: 06/21/2013] [Indexed: 12/20/2022]
Abstract
OBJECTIVE S100A4 is a Ca-binding protein that regulates cell growth, survival, and motility. The abundant expression of S100A4 in rheumatiod arthritis contributes to the invasive growth of joint tissue and to bone damage. In the present study, we analysed the role of S100A4 in bone homeostasis. METHODS Peripheral quantitative computed tomography and histomorphometric analysis were performed in mice lacking the entire S100A4 protein (S100A4KO) and in wild-type (WT) counterparts treated with shRNA-lentiviral constructs targeting S100A4 (S100A4-shRNA). Control groups consisted of sex-matched WT counterparts and WT mice treated with a non-targeting RNA construct. RESULTS S100A4 deficiency was associated with higher trabecular and cortical bone mass, increased number and thickness of trabeculi combined with larger periosteal circumference and higher predicted bone strength. S100A4 inhibition by shRNA led to an increase in cortical bone in WT mice. S100A4-deficieny was associated with a reduced number of functional osteoclasts. S100A4KO and S100A4-shRNA-treated bone marrow progenitors gave rise to a large number of small TRAP+ cells with few nuclei and few pseudopodial processes. Poor osteoclastogenesis and the low resorptive capacity in S100A4Ko mice may be linked to low levels of surface integrins, impaired adhesion capacity, and poor multinucleation in S100A4-deficient osteoclasts, as well as a low content of proteolytic enzymes cathepsin K and MMP3 and MMP9 to break down the organic matrix. CONCLUSION S100A4 emerges as a negative regulator of bone metabolism potentially responsible for the excessive bone turnover in conditions marked by high levels of S100A4 protein, such as inflammation and rheumatoid arthritis.
Collapse
Affiliation(s)
- Malin C Erlandsson
- Department of Rheumatology and Inflammation Research at Sahlgrenska Academy, University of Göteborg, Göteborg, Sweden
| | - Mattias D Svensson
- Department of Rheumatology and Inflammation Research at Sahlgrenska Academy, University of Göteborg, Göteborg, Sweden
| | - Ing-Marie Jonsson
- Department of Rheumatology and Inflammation Research at Sahlgrenska Academy, University of Göteborg, Göteborg, Sweden
| | - Li Bian
- Department of Rheumatology and Inflammation Research at Sahlgrenska Academy, University of Göteborg, Göteborg, Sweden
| | | | - Sofia Andersson
- Department of Rheumatology and Inflammation Research at Sahlgrenska Academy, University of Göteborg, Göteborg, Sweden
| | | | | | - Claes Ohlsson
- Center for Bone and Arthritis Research at Sahlgrenska Academy, University of Göteborg, Göteborg, Sweden
| | - Karin M E Andersson
- Department of Rheumatology and Inflammation Research at Sahlgrenska Academy, University of Göteborg, Göteborg, Sweden
| | - Maria I Bokarewa
- Department of Rheumatology and Inflammation Research at Sahlgrenska Academy, University of Göteborg, Göteborg, Sweden.
| |
Collapse
|
78
|
Boyce BF, Rosenberg E, de Papp AE, Duong LT. The osteoclast, bone remodelling and treatment of metabolic bone disease. Eur J Clin Invest 2012; 42:1332-41. [PMID: 22998735 DOI: 10.1111/j.1365-2362.2012.02717.x] [Citation(s) in RCA: 125] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
BACKGROUND Bone remodelling maintains skeletal integrity by osteoclasts removing foci of damaged bone and osteoblasts replacing them with new bone. Diseases associated with increased bone resorption have increased remodelling often with inadequate bone formation and increased risk of fracture. New therapies are needed for these diseases to reduce resorption and increase formation. DESIGN The molecular mechanisms regulating osteoclast and osteoblast functions have become better understood in the past 20 years and have led to questioning of the long-held notion that osteoblastic cells have the dominant regulatory role over osteoclastic cells in bone remodelling. Here, we review current knowledge of how osteoclast formation and functions are regulated and describe how enhanced understanding of these has led to development of new drugs for the management of common bone diseases characterized by increased bone resorption. RESULTS Osteoclast formation and functions are regulated by cytokines, especially receptor activator of NF-κB ligand (RANKL) and macrophage-colony-stimulating factor (M-CSF). The differentiation, activity and lifecycle of osteoclasts are regulated in part by other cells that reside within the bone. These include osteoblasts, osteocytes and immune cells, which express these cytokines in response to most factors that promote bone resorption. RANKL and M-CSF activate numerous signalling pathways, which are potential targets for therapeutic intervention. Importantly, osteoclastic cells also function as positive and negative regulators of osteoblastic bone formation. CONCLUSIONS There are multiple targets within osteoclasts for pharmacologic intervention to prevent bone loss in osteoporosis and other resorptive bone diseases. However, novel therapies could also affect osteoblastic cell functions.
Collapse
Affiliation(s)
- Brendan F Boyce
- Department ofPathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA.
| | | | | | | |
Collapse
|
79
|
Roy S, Dattagupta J, Biswas S. Expression of recombinant human cathepsin K is enhanced by codon optimization. Process Biochem 2012. [DOI: 10.1016/j.procbio.2012.06.029] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
80
|
Dubern B, Lafarge JC, Fellahi S, Naour N, Copin N, Bastard JP, Simon C, Clément K, Bonnet D, Tounian P, Guerre-Millo M. Relevance of increased serum cystatin C to vascular alterations in obese children. Pediatr Obes 2012; 7:374-81. [PMID: 22653843 DOI: 10.1111/j.2047-6310.2012.00053.x] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/10/2011] [Revised: 01/15/2012] [Accepted: 02/08/2012] [Indexed: 10/28/2022]
Abstract
OBJECTIVE Epidemiological studies report a positive relationship between serum cystatin C and cardiovascular outcomes in adults. Here, we tested the relevance of cystatin C as a biomarker for early vascular alterations in severely obese children. METHODS Two hundred nineteen obese (140 girls; age = 11.7 ± 2.7 years, BMI Z-score = 4.7 ± 1.2 SD) and 262 non-obese children (129 girls; age = 11.6 ± 0.6 years, body mass index [BMI] Z-score = 0.1 ± 1.0 SD). Serum cystatin C was measured by immunonephelometry. Intima media thickness (IMT), incremental elastic modulus, and flow-mediated and glyceryl-trinitrate-mediated dilations were determined at the common carotid artery and the brachial artery in obese children. RESULTS Obese children had significantly higher serum cystatin C than normal weight controls (0.86 ± 0.01 vs. 0.80 ± 0.01, P < 0.0001). In obese children, serum cystatin C correlates positively with BMI and the homeostasis model assessment index and negatively with the quantitative insulin sensitivity check index and adiponectin. A positive relationship was found between serum cystatin C and carotid IMT (r = 0.23, P = 0.0005), which remained significant in multivariate models adjusted for BMI (P = 0.01) and adiponectin with a trend towards significance (P = 0.05). CONCLUSION This study positions cystatin C and adiponectin as covariables associated with arterial wall thickness in obese children. Although the underlying pathophysiology linking cystatin C to early vascular disease remains to be deciphered, cystatin C may represent a novel adipose tissue-derived biomarker implicated in obesity-related comorbidities early in life.
Collapse
Affiliation(s)
- B Dubern
- Institute of Cardiometabolism and Nutrition, Paris, France; INSERM, Paris, France
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
81
|
Extract of Magnoliae Flos inhibits ovariectomy-induced osteoporosis by blocking osteoclastogenesis and reducing osteoclast-mediated bone resorption. Fitoterapia 2012; 83:1523-31. [PMID: 22981503 DOI: 10.1016/j.fitote.2012.08.020] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2012] [Revised: 08/28/2012] [Accepted: 08/28/2012] [Indexed: 11/20/2022]
Abstract
Bone homeostasis is maintained by a balance between bone resorption by osteoclasts and bone formation by osteoblasts. Osteoporosis occurs when osteoclast activity surpasses osteoblast activity. Pro-inflammatory cytokines stimulate osteoclast differentiation and activity by increasing production of macrophage-colony stimulating factor and receptor activator of nuclear factor-κB ligand (RANKL). In this study, we investigated whether Magnoliae Flos (MF), one of the most commonly used Chinese medicinal herbs for managing rhinitis, sinusitis and headache, could effectively inhibit osteoporosis. In ovariectomized (OVX) mice compared to sham mice, the body weight increased and serum levels of alkaline phosphatase (ALP), tartrate resistant acid phosphatase 5b, calcium, and osteocalcin were significantly elevated. However, orally administrated MF extract substantially inhibited the increased body weight and serum levels of bone turnover markers, without any evidence of tissue toxicity. MF extract treatment significantly reversed the morphometric parameters of ovariectomy-induced bone loss, including trabecular bone volume, thickness, number, separation, and bone density, to almost the same levels of the sham mice. Furthermore, MF extract reduced the RANKL-mediated osteoclast differentiation and bone resorption by inhibiting the activities of matrix metalloproteinases (MMPs) and cathepsin K in mouse bone marrow macrophages. MF extract appeared to increase ALP activity in murine osteoblastic cells. Taken together, MF extract may be a beneficial supplement for the blockade of osteoporosis progression, particularly for the management of postmenopausal osteoporosis.
Collapse
|
82
|
Optimizing dentin bond durability: control of collagen degradation by matrix metalloproteinases and cysteine cathepsins. Dent Mater 2012; 29:116-35. [PMID: 22901826 DOI: 10.1016/j.dental.2012.08.004] [Citation(s) in RCA: 294] [Impact Index Per Article: 24.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2012] [Revised: 08/04/2012] [Accepted: 08/05/2012] [Indexed: 11/21/2022]
Abstract
OBJECTIVES Contemporary adhesives lose their bond strength to dentin regardless of the bonding system used. This loss relates to the hydrolysis of collagen matrix of the hybrid layers. The preservation of the collagen matrix integrity is a key issue in the attempts to improve the dentin bonding durability. METHODS Dentin contains collagenolytic enzymes, matrix metalloproteinases (MMPs) and cysteine cathepsins, which are responsible for the hydrolytic degradation of collagen matrix in the bonded interface. RESULTS The identities, roles and function of collagenolytic enzymes in mineralized dentin has been gathered only within last 15 years, but they have already been demonstrated to have an important role in dental hard tissue pathologies, including the degradation of the hybrid layer. Identifying responsible enzymes facilitates the development of new, more efficient methods to improve the stability of dentin-adhesive bond and durability of bond strength. SIGNIFICANCE Understanding the nature and role of proteolytic degradation of dentin-adhesive interfaces has improved immensely and has practically grown to a scientific field of its own within only 10 years, holding excellent promise that stable resin-dentin bonds will be routinely available in a daily clinical setting already in a near future.
Collapse
|
83
|
Pérez-Castrillón JL, Pinacho F, Ruiz-Mambrilla M, Dueñas Laita A. Odanacatib: a possible new therapeutic option for the treatment of osteoporosis. ACTA ACUST UNITED AC 2012. [DOI: 10.2217/ijr.12.33] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|
84
|
Mazzoni A, Breschi L, Carrilho M, Nascimento FD, Orsini G, Ruggeri A, Gobbi P, Manzoli L, Tay FR, Pashley DH, Tjäderhane L. A review of the nature, role, and function of dentin non-collagenous proteins. Part II: enzymes, serum proteins, and growth factors. ACTA ACUST UNITED AC 2012. [DOI: 10.1111/j.1601-1546.2012.00268.x] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
85
|
Khedr NF, El-Ashmawy NE, El-Bahrawy HA, Haggag AA, El-Abd EE. Modulation of bone turnover in orchidectomized rats treated with raloxifene and risedronate. Fundam Clin Pharmacol 2012; 27:526-34. [PMID: 22762129 DOI: 10.1111/j.1472-8206.2012.01047.x] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2011] [Revised: 04/15/2012] [Accepted: 05/11/2012] [Indexed: 11/27/2022]
Abstract
Osteoporosis is a reduction in bone mineral density (BMD). It develops less often in men than in women. This study aimed to evaluate the bone protective effects of raloxifene (RAL), risedronate (RIS), and their combination on osteoporotic male rats. Forty male Wister rats (12 weeks) were randomly divided into five groups: sham-operated group (n = 8), orchidectomized (ORX) group (n = 7), RAL group (n = 9), RIS group (n = 7) and RAL + RIS group (n = 7). RAL was orally administered at 3 mg/kg three times/week, and RIS was given subcutaneously at 5 μg/kg, twice weekly. After 6 weeks of treatment, serum cathepsin-K, alkaline (ALP) and acid phosphatase activities, serum osteocalcin, serum Ca²⁺, and Pi were determined. Urinary Ca²⁺ and deoxypyridinoline levels, BMD, and Ca²⁺ content of femur ash were estimated. Histochemical localization of ALP activity of tibia and histomorphometry was examined. As compared to sham, ORX rats showed a significant increase in bone turnover markers, and histochemical activity of ALP was increased markedly in proximal tibia of ORX rats, whereas BMD and Ca²⁺ content of femur ash were reduced after ORX. These changes were modulated after treatment with RAL and RIS or both to ORX rats; BMD of femur was improved by each treatment, and bone turnover markers were reduced as compared to ORX vehicle group. We concluded that orchidectomy induced osteoporosis and increased bone turnover in male rats because of withdrawal of sex hormones. Both RAL and RIS could treat osteoporosis in ORX rats; they reduced bone turnover markers and maintained BMD.
Collapse
Affiliation(s)
- Naglaa F Khedr
- Department of Biochemistry, Faculty of Pharmacy, Tanta University, Gharbia, 31527, Egypt.
| | | | | | | | | |
Collapse
|
86
|
Barry ZT, Platt MO. Cathepsin S cannibalism of cathepsin K as a mechanism to reduce type I collagen degradation. J Biol Chem 2012; 287:27723-30. [PMID: 22730330 DOI: 10.1074/jbc.m111.332684] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Cathepsins S and K are potent mammalian proteases secreted into the extracellular space and have been implicated in elastin and collagen degradation in diseases such as atherosclerosis and osteoporosis. Studies of individual cathepsins hydrolyzing elastin or collagen have provided insight into their binding and kinetics, but cooperative or synergistic activity between cathepsins K and S is less described. Using fluorogenic substrate assays, Western blotting, cathepsin zymography, and computational analyses, we uncovered cathepsin cannibalism, a novel mechanism by which cathepsins degrade each other as well as the substrate, with cathepsin S predominantly degrading cathepsin K. As a consequence of these proteolytic interactions, a reduction in total hydrolysis of elastin and type I collagen was measured compared with computationally predicted values derived from individual cathepsin assays. Furthermore, type I collagen was preserved from hydrolysis when a 10-fold ratio of cathepsin S cannibalized the highly collagenolytic cathepsin K, preventing its activity. Elastin was not preserved due to strong elastinolytic ability of both enzymes. Together, these results provide new insight into the combined proteolytic activities of cathepsins toward substrates and each other and present kinetic models to consider for more accurate predictions and descriptions of these systems.
Collapse
Affiliation(s)
- Zachary T Barry
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia 30332, USA
| | | |
Collapse
|
87
|
Brisson L, Reshkin SJ, Goré J, Roger S. pH regulators in invadosomal functioning: proton delivery for matrix tasting. Eur J Cell Biol 2012; 91:847-60. [PMID: 22673002 DOI: 10.1016/j.ejcb.2012.04.004] [Citation(s) in RCA: 59] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2012] [Revised: 04/18/2012] [Accepted: 04/19/2012] [Indexed: 12/20/2022] Open
Abstract
Invadosomes are actin-rich finger-like cellular structures sensing and interacting with the surrounding extracellular matrix (ECM) and involved in its proteolytic remodeling. Invadosomes are structures distinct from other adhesion complexes, and have been identified in normal cells that have to cross tissue barriers to fulfill their function such as leukocytes, osteoclasts and endothelial cells. They also represent features of highly aggressive cancer cells, allowing them to escape from the primary tumor, to invade surrounding tissues and to reach systemic circulation. They are localized to the ventral membrane of cells grown under 2-dimensional conditions and are supposed to be present all around cells grown in 3-dimensional matrices. Indeed invadosomes are key structures in physiological processes such as inflammation and the immune response, bone remodeling, tissue repair, but also in pathological conditions such as osteopetrosis and the development of metastases. Invadosomes are subdivided into podosomes, found in normal cells, and into invadopodia specific for cancer cells. While these two structures exhibit differences in organization, size, number and half-life, they share similarities in molecular composition, participation in cell-matrix adhesion and promoting matrix degradation. A key determinant in invadosomal function is the recruitment and release of proteases, such as matrix metalloproteinases (MMPs), serine proteases and cysteine cathepsins, together with their activation in a tightly controlled and highly acidic microenvironment. Therefore numerous pH regulators such as V-ATPases and Na(+)/H(+) exchangers, are found in invadosomes and are directly involved in their constitution as well as their functioning. This review focuses on the participation of pH regulators in invadosome function in physiological and pathological conditions, with a particular emphasis on ECM remodeling by osteoclasts during bone resorption and by cancer cells.
Collapse
Affiliation(s)
- Lucie Brisson
- Nutrition, Growth and Cancer, Université François-Rabelais de Tours, Inserm U, France
| | | | | | | |
Collapse
|
88
|
Duong LT. Therapeutic inhibition of cathepsin K-reducing bone resorption while maintaining bone formation. BONEKEY REPORTS 2012; 1:67. [PMID: 23951460 DOI: 10.1038/bonekey.2012.67] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/09/2012] [Accepted: 03/08/2012] [Indexed: 01/12/2023]
Abstract
Osteoporosis is a disease of high bone remodeling with an imbalance of bone resorption over bone formation, resulting in decreased bone mineral density and deterioration of bone microarchitecture. From the emerging understandings of the molecular and cellular regulators of bone remodeling, potential new targets for therapeutic intervention for this disease have been identified. Cathepsin K (CatK), a cysteine protease produced by osteoclasts, is the primary enzyme mediating the degradation of the demineralized bone matrix. Current genetic and pharmacological evidence from studies in multiple preclinical species have consistently demonstrated that inhibition of CatK results in the reduction of bone resorption while allowing bone formation to continue. Early results from clinical studies with several investigational CatK inhibitors indicate that the impact of CatK inhibition on bone formation is distinct from that of either the bisphosphonates or the anti-receptor activator of nuclear factor-κB ligand antibody, denosumab. Odanacatib, a highly selective, reversible and potent inhibitor of CatK, is currently in phase III clinical trials for the treatment of postmenopausal osteoporosis.
Collapse
Affiliation(s)
- Le T Duong
- Department of Bone Biology, Merck Research Laboratories , West Point, PA, USA
| |
Collapse
|
89
|
Novinec M, Lenarčič B, Baici A. Clusterin is a specific stabilizer and liberator of extracellular cathepsin K. FEBS Lett 2012; 586:1062-6. [PMID: 22569264 DOI: 10.1016/j.febslet.2012.03.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2012] [Revised: 03/02/2012] [Accepted: 03/04/2012] [Indexed: 10/28/2022]
Abstract
The cysteine peptidase cathepsin K is a major player in extracellular proteolysis. Here we describe the identification of the multifunctional extracellular chaperone clusterin as a cathepsin K-binding protein. Clusterin increases the stability of cathepsin K in dilute solution and in the presence of high protein concentration. It does not alter the activity of the enzyme but acts as a liberator by preventing substrate inhibition. Kinetic measurements show that clusterin binds cathepsin K with high affinity (K(d) = 0.5-0.6 nM). Altogether these results provide novel insights into the mechanisms involved in the fine-tuning of cysteine cathepsin activity in the extracellular space.
Collapse
Affiliation(s)
- Marko Novinec
- Department of Chemistry and Biochemistry, Faculty of Chemistry and Chemical Technology, University of Ljubljana, 1000 Ljubljana, Slovenia.
| | | | | |
Collapse
|
90
|
Boonen S, Rosenberg E, Claessens F, Vanderschueren D, Papapoulos S. Inhibition of cathepsin K for treatment of osteoporosis. Curr Osteoporos Rep 2012; 10:73-9. [PMID: 22228398 DOI: 10.1007/s11914-011-0085-9] [Citation(s) in RCA: 78] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Cathepsin K is the protease that is primarily responsible for the degradation of bone matrix by osteoclasts. Inhibitors of cathepsin K are in development for treatment of osteoporosis. Currently available antiresorptive drugs interfere with osteoclast function. They inhibit both bone resorption and formation, due to the coupling between these processes. Cathepsin K inhibitors, conversely, target the resorption process itself and may not interfere with osteoclast stimulation of bone formation. In fact, when cathepsin K is absent or inhibited in mice, rabbits, or monkeys, bone formation is maintained or increased. In humans, inhibition of cathepsin K is associated with sustained reductions in bone resorption markers but with smaller and transient reductions in bone formation markers. The usefulness of cathepsin K inhibitors in osteoporosis is now being examined in phase 2 and phase 3 clinical trials of postmenopausal osteoporotic women.
Collapse
Affiliation(s)
- Steven Boonen
- Leuven University Division of Geriatric Medicine and Centre for Metabolic Bone Diseases, UZ Leuven campus Gasthuisberg, Herestraat 49, B-3000 Leuven, Belgium.
| | | | | | | | | |
Collapse
|
91
|
Rosa RG, Tarsitano CAB, Hyslop S, Yamada AT, Toledo OMS, Joazeiro PP. Temporal changes in matrix metalloproteinases, their inhibitors, and cathepsins in mouse pubic symphysis during pregnancy and postpartum. Reprod Sci 2012; 18:963-77. [PMID: 21960510 DOI: 10.1177/1933719111401657] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
Remodeling and relaxation of the mouse pubic symphysis (PS) are central events in parturition. The involvement of endogenous proteins such as matrix metalloproteinases (MMPs), tissue inhibitors of matrix metalloproteinases (TIMPs), and cathepsins in these phenomena remains unclear. In this work, we used a combination of immunolocalization, protein expression/activity, and relative messenger RNA (mRNA) expression to examine the changes in selected MMPs (-2, -9, and -8), TIMPs (-1 and -2), and cathepsins (B and K) during pregnancy and postpartum in mice. Immunohistochemistry revealed the presence of all of these proteins in the cytoplasm of chondrocytes, fibrochondrocytes, and fibroblast-like cells in the interpubic tissues. Zymography showed increases in the active forms of MMP-2 and -9 primarily on days 15 to 19 of pregnancy. Western blotting showed enhanced expression of MMP-8 on days 12 to 15 of pregnancy, with no changes in cathepsins B and K. Matrix metalloproteinases 2, TIMP-1 and -2, and cathepsin B had significant relative gene expression throughout pregnancy. These findings indicate that during pregnancy and postpartum there are variations in the expression and activity of proteins that may have an important role in remodeling the pubic symphysis during these events.
Collapse
Affiliation(s)
- Renata G Rosa
- Department of Histology and Embryology, Institute of Biology, State University of Campinas (UNICAMP), Campinas, SP, Brazil
| | | | | | | | | | | |
Collapse
|
92
|
McKenzie JA, Bixby EC, Silva MJ. Differential gene expression from microarray analysis distinguishes woven and lamellar bone formation in the rat ulna following mechanical loading. PLoS One 2011; 6:e29328. [PMID: 22216249 PMCID: PMC3245266 DOI: 10.1371/journal.pone.0029328] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2011] [Accepted: 11/26/2011] [Indexed: 12/21/2022] Open
Abstract
Formation of woven and lamellar bone in the adult skeleton can be induced through mechanical loading. Although much is known about the morphological appearance and structural properties of the newly formed bone, the molecular responses to loading are still not well understood. The objective of our study was to use a microarray to distinguish the molecular responses between woven and lamellar bone formation induced through mechanical loading. Rat forelimb loading was completed in a single bout to induce the formation of woven bone (WBF loading) or lamellar bone (LBF loading). A set of normal (non-loaded) rats were used as controls. Microarrays were performed at three timepoints after loading: 1 hr, 1 day and 3 days. Confirmation of microarray results was done for a select group of genes using quantitative real-time PCR (qRT-PCR). The micorarray identified numerous genes and pathways that were differentially regulated for woven, but not lamellar bone formation. Few changes in gene expression were evident comparing lamellar bone formation to normal controls. A total of 395 genes were differentially expressed between formation of woven and lamellar bone 1 hr after loading, while 5883 and 5974 genes were differentially expressed on days 1 and 3, respectively. Results suggest that not only are the levels of expression different for each type of bone formation, but that distinct pathways are activated only for woven bone formation. A strong early inflammatory response preceded an increase in angiogenic and osteogenic gene expression for woven bone formation. Furthermore, at later timepoints there was evidence of bone resorption after WBF loading. In summary, the vast coverage of the microarray offers a comprehensive characterization of the early differences in expression between woven and lamellar bone formation.
Collapse
Affiliation(s)
- Jennifer A McKenzie
- Department of Orthopaedics, Washington University, St. Louis, Missouri, USA.
| | | | | |
Collapse
|
93
|
Wilder CL, Park KY, Keegan PM, Platt MO. Manipulating substrate and pH in zymography protocols selectively distinguishes cathepsins K, L, S, and V activity in cells and tissues. Arch Biochem Biophys 2011; 516:52-7. [PMID: 21982919 PMCID: PMC3221864 DOI: 10.1016/j.abb.2011.09.009] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2011] [Revised: 09/23/2011] [Accepted: 09/25/2011] [Indexed: 11/15/2022]
Abstract
Cathepsins K, L, S, and V are cysteine proteases that have been implicated in tissue-destructive diseases such as atherosclerosis, tumor metastasis, and osteoporosis. Among these four cathepsins are the most powerful human collagenases and elastases, and they share 60% sequence homology. Proper quantification of mature, active cathepsins has been confounded by inhibitor and reporter substrate cross-reactivity, but is necessary to develop properly dosed therapeutic applications. Here, we detail a method of multiplex cathepsin zymography to detect and distinguish the activity of mature cathepsins K, L, S, and V by exploiting differences in individual cathepsin substrate preferences, pH effects, and electrophoretic mobility under non-reducing conditions. Specific identification of cathepsins K, L, S, and V in one cell/tissue extract was obtained with cathepsin K (37 kDa), V (35 kDa), S (25 kDa), and L (20 kDa) under non-reducing conditions. Cathepsin K activity disappeared and V remained when incubated at pH 4 instead of 6. Application of this antibody free, species independent, and medium-throughput method was demonstrated with primary human monocyte-derived macrophages and osteoclasts, endothelial cells stimulated with inflammatory cytokines, and normal and cancer lung tissues, which identified elevated cathepsin V in lung cancer.
Collapse
Affiliation(s)
- Catera L. Wilder
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332
| | - Keon-Young Park
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332
| | - Philip M. Keegan
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332
| | - Manu O. Platt
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332
| |
Collapse
|
94
|
Cysteine cathepsins: from structure, function and regulation to new frontiers. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS 2011; 1824:68-88. [PMID: 22024571 PMCID: PMC7105208 DOI: 10.1016/j.bbapap.2011.10.002] [Citation(s) in RCA: 878] [Impact Index Per Article: 67.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/16/2011] [Revised: 10/03/2011] [Accepted: 10/04/2011] [Indexed: 02/06/2023]
Abstract
It is more than 50 years since the lysosome was discovered. Since then its hydrolytic machinery, including proteases and other hydrolases, has been fairly well identified and characterized. Among these are the cysteine cathepsins, members of the family of papain-like cysteine proteases. They have unique reactive-site properties and an uneven tissue-specific expression pattern. In living organisms their activity is a delicate balance of expression, targeting, zymogen activation, inhibition by protein inhibitors and degradation. The specificity of their substrate binding sites, small-molecule inhibitor repertoire and crystal structures are providing new tools for research and development. Their unique reactive-site properties have made it possible to confine the targets simply by the use of appropriate reactive groups. The epoxysuccinyls still dominate the field, but now nitriles seem to be the most appropriate “warhead”. The view of cysteine cathepsins as lysosomal proteases is changing as there is now clear evidence of their localization in other cellular compartments. Besides being involved in protein turnover, they build an important part of the endosomal antigen presentation. Together with the growing number of non-endosomal roles of cysteine cathepsins is growing also the knowledge of their involvement in diseases such as cancer and rheumatoid arthritis, among others. Finally, cysteine cathepsins are important regulators and signaling molecules of an unimaginable number of biological processes. The current challenge is to identify their endogenous substrates, in order to gain an insight into the mechanisms of substrate degradation and processing. In this review, some of the remarkable advances that have taken place in the past decade are presented. This article is part of a Special Issue entitled: Proteolysis 50 years after the discovery of lysosome.
Collapse
|
95
|
Luhmann T, Germershaus O, Groll J, Meinel L. Bone targeting for the treatment of osteoporosis. J Control Release 2011; 161:198-213. [PMID: 22016072 DOI: 10.1016/j.jconrel.2011.10.001] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2011] [Revised: 10/01/2011] [Accepted: 10/03/2011] [Indexed: 11/19/2022]
Abstract
Osteoporosis represents a major public health burden especially considering the aging populations worldwide. Drug targeting will be important to better meet these challenges and direct the full therapeutic potential of therapeutics to their intended site of action. This review has been organized in modules, such that scientists working in the field can easily gain specific insight in the field of bone targeting for the drug class they are interested in. We review currently approved and emerging treatment options for osteoporosis and discuss these in light of the benefit these would gain from advanced targeting. In addition, established targeting strategies are reviewed and novel opportunities as well as promising areas are presented along with pharmaceutical strategies how to render novel composites consisting of a drug and a targeting moiety responsive to bone-specific or disease-specific environmental stimuli. Successful implementation of these principles into drug development programs for osteoporosis will substantially contribute to the clinical success of anti-catabolic and anabolic drugs of the future.
Collapse
Affiliation(s)
- Tessa Luhmann
- Institute for Pharmacy and Food Chemistry, University of Wurzburg, Am Hubland, DE-97074 Wurzburg, Germany
| | | | | | | |
Collapse
|
96
|
Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis? Future Med Chem 2011; 1:21-34. [PMID: 20126511 DOI: 10.4155/fmc.09.4] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND Until fairly recently, cathepsin K was recognized solely as a bone-resorbing enzyme expressed selectively in the osteoclast. Evidence of its requirement for normal bone remodeling has resulted in this protease receiving considerable attention from the pharmaceutical industry. In the last decade, intense research efforts were aimed at development of cathepsin K inhibitors for treatment of osteoporosis and other skeletal disorders associated with pathological bone loss. Emerging new evidence suggests that in addition to bone resorption, cathepsin K is involved in the turnover of extracellular matrix proteins in organs, such as the lung, thyroid and skin, and plays important roles in cardiovascular disease, inflammation and obesity. DISCUSSION This review highlights the physiological and pathophysiological implications of this potent protease, with a focus on recent developments in the design and use of cathepsin K inhibitors to target skeletal pathologies. Therapeutic implications of anticathepsin K drugs in the context of common links between bone disease and atherosclerosis are also discussed. CONCLUSION The association of cathepsin K with skeletal and cardiovascular disorders offers intriguing future applications for inhibitors of this potent protease.
Collapse
|
97
|
Costa AG, Cusano NE, Silva BC, Cremers S, Bilezikian JP. Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis. Nat Rev Rheumatol 2011; 7:447-56. [PMID: 21670768 DOI: 10.1038/nrrheum.2011.77] [Citation(s) in RCA: 197] [Impact Index Per Article: 15.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
Bone remodeling consists of two phases--bone resorption and bone formation--that are normally balanced. When bone resorption exceeds bone formation, pathologic processes, such as osteoporosis, can result. Cathepsin K is a member of the papain family of cysteine proteases that is highly expressed by activated osteoclasts. Cathepsin K readily degrades type I collagen, the major component of the organic bone matrix. With such a major role in the initial process of bone resorption, cathepsin K has become a therapeutic target in osteoporosis. The antiresorptive properties of cathepsin K inhibitors have been studied in phase I and phase II clinical trials. Phase III studies are currently underway for odanacatib, a selective cathepsin K inhibitor.
Collapse
Affiliation(s)
- Aline G Costa
- Metabolic Bone Diseases Unit, Division of Endocrinology, Department of Medicine, College of Physicians and Surgeons, Columbia University, 630 W. 168th Street, New York, NY 10032, USA
| | | | | | | | | |
Collapse
|
98
|
Kasabova M, Saidi A, Naudin C, Sage J, Lecaille F, Lalmanach G. Cysteine Cathepsins: Markers and Therapy Targets in Lung Disorders. Clin Rev Bone Miner Metab 2011. [DOI: 10.1007/s12018-011-9094-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
|
99
|
|
100
|
Rünger TM, Adami S, Benhamou CL, Czerwiński E, Farrerons J, Kendler DL, Mindeholm L, Realdi G, Roux C, Smith V. Morphea-like skin reactions in patients treated with the cathepsin K inhibitor balicatib. J Am Acad Dermatol 2011; 66:e89-96. [PMID: 21571394 DOI: 10.1016/j.jaad.2010.11.033] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2010] [Revised: 11/16/2010] [Accepted: 11/20/2010] [Indexed: 10/18/2022]
Abstract
BACKGROUND In a multicenter clinical trial in North America and Europe that tested the cathepsin K (catK) inhibitor balicatib for the treatment of osteoporosis, several patients developed hardening of the skin. OBJECTIVE We sought to characterize these observed adverse events. METHODS Patients with skin hardening were examined by a local dermatologist. All of those patients except one had at least one biopsy specimen taken from affected skin, which was read by local and two central dermatopathologists. Workup was directed for consideration of systemic scleroderma. RESULTS Nine patients of 709 treated with balicatib developed skin hardening and were given a diagnosis of morphea-like skin changes. No such events were observed in patients taking placebo or the lowest balicatib dose. After discontinuation of balicatib, skin changes resolved completely in 8 and partially in one patient. LIMITATIONS Each patient was seen by a different dermatologist in 6 different countries. CONCLUSIONS These observations are likely dose-related adverse effects of balicatib. Although catK was originally thought to be expressed only in osteoclasts, it has more recently also been found in lung and dermal fibroblasts and been implicated in the degradation of the extracellular matrix in the lung and the skin. It is therefore plausible that the observed dermal fibrosis in balicatib-treated patients is a result of impaired degradation of extracellular matrix proteins and may represent a class effect of catK inhibitors. We recommend that further exploration of catK inhibition for the treatment of osteoporosis or cancer should include monitoring for similar adverse effects.
Collapse
Affiliation(s)
- Thomas M Rünger
- Department of Dermatology, Boston University School of Medicine, Boston, Massachusetts 02118, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|